Background-Anemia is common among patients hospitalized with acute myocardial infarction and is associated with poor outcomes. Less is known about the incidence, correlates, and prognostic implications of acute, hospital-acquired anemia (HAA). Methods and Results-We identified 2909 patients with acute myocardial infarction who had normal hemoglobin (Hgb) on admission in the multicenter TRIUMPH registry and defined HAA by criteria proposed by Beutler and Waalen. We used hierarchical Poisson regression to identify independent correlates of HAA and multivariable proportional hazards regression to identify the association of HAA with mortality and health status. At discharge, 1321 (45.4%) patients had HAA, of whom 348 (26.3%) developed moderate-severe HAA (Hgb Ͻ11 g/dL). The incidence of HAA varied significantly across hospitals (range, 33% to 69%; median rate ratio for HAA, 1.13; 95% confidence interval, 1.07 to 1.23, adjusting for patient characteristics). Although documented bleeding was more frequent with more severe HAA, fewer than half of the patients with moderate-severe HAA had any documented bleeding. Independent correlates of HAA included age, female sex, white race, chronic kidney disease, ST-segment elevation myocardial infarction, acute renal failure, use of glycoprotein IIb/IIIa inhibitors, in-hospital complications (cardiogenic shock, bleeding and bleeding severity), and length of stay. After adjustment for GRACE score and bleeding, patients with moderate-severe HAA had higher mortality rates (hazard ratio, 1.82; 95% confidence interval, 1.11 to 2.98 versus no HAA) and poorer health status at 1 year. Conclusions-HAA develops in nearly half of acute myocardial infarction hospitalizations among patients treated medically or with percutaneous coronary intervention, commonly in the absence of documented bleeding, and is associated with worse mortality and health status. Better understanding of how HAA can be prevented and whether its prevention can improve patient outcomes is needed. (Circ Cardiovasc Qual Outcomes. 2010;3:337-346.)
A nemia is common in patients hospitalized with acute myocardial infarction (AMI) and is associated with increased mortality rates, [1] [2] [3] [4] higher hospitalization rates, 5 and worse health-related quality of life. 6 However, most prior studies of anemia in the setting of AMI have evaluated chronic anemia (present at admission) or short-term changes in hemoglobin during hospitalization. 7 Little research has focused on hospital-acquired anemia (HAA), which develops acutely during AMI admission in those with normal baseline hemoglobin (Hgb). Given that the etiology of HAA, an acute phenomenon, is likely to be different from that of chronic anemia, it is important to understand the risk factors for its development and its prognostic implications.
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Chronic anemia is often due to nutritional deficiencies, chronic inflammation, and renal or bone marrow disorders and can be difficult to manage. In contrast, HAA may be more likely to result from in-hospital treatments and processes of care. If associated with adverse outcomes, HAA may be preventable and could represent an actionable target for hospital-based quality improvement efforts. Potential benefits of preventing HAA may include reducing patients' exposure to the risks from acute anemia treatments such as blood transfusion, 8 improving clinical outcomes, and reducing costs. However, before resources are directed to HAA prevention, it is necessary to better understand the incidence and predictors of HAA and its association with clinically relevant outcomes.
To address these gaps in knowledge, we sought to describe the incidence and predictors of HAA, the variation in HAA prevalence between hospitals, and its relationship with subsequent mortality and health status outcomes in the Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status study (TRIUMPH), a prospective 24-center observational registry of AMI treatment and outcomes. TRIUMPH provided an ideal opportunity to address these important questions, as it collected detailed patient data on in-hospital hemoglobin, hospital-based treatments, complications and processes of care, as well as serial assessments of patient outcomes after discharge.
WHAT IS KNOWN
• Prior literature has described a strong association between chronic anemia and poor outcomes after acute myocardial infarction including higher mortality rates and worse health-related quality of life, but the prognostic implications of acute, hospitalacquired anemia (HAA) are unclear.
WHAT THE STUDY ADDS
• HAA develops in nearly half of acute myocardial infarction patients treated medically or with percutaneous coronary intervention, and its incidence varies across hospitals. • Inpatient bleeding is a strong independent predictor of HAA, but many patients with HAA do not have a documented bleeding event during hospitalization, suggesting that HAA is not simply a surrogate for in-hospital bleeding. • Moderate-severe HAA is associated with greater mortality rates and worse health status in the first year after acute myocardial infarction.
Methods

TRIUMPH Study
A total of 4340 patients were enrolled in TRIUMPH between April 11, 2005 , and December 31, 2008. Patients were Ն18 years of age, with elevated cardiac biomarkers (troponin or creatine kinase-MB fraction assessed within 24 hours of admission) and supporting evidence of AMI (ECG ST-segment changes or prolonged ischemic signs/symptoms). Participants were required to either present to the enrolling institution or to have been transferred within 24 hours of symptom onset so that the primary clinical decision-making occurred at the enrolling center. Patients with elevated cardiac biomarkers resulting from an elective coronary revascularization were excluded. Trained data collectors performed detailed baseline chart abstractions to document patients' medical history, the processes of inpatient care, laboratory results, and treatments. Each patient underwent a standardized interview by research staff to document sociodemographic and clinical data. Patients were contacted for follow-up interviews at 1, 6, and 12 months after AMI. All patients signed an informed consent approved by the participating institution, and institutional review board approval was obtained at each participating center.
Study Population
The goals of this study were to describe the incidence, correlates, and outcomes of HAA in patients surviving AMI hospitalization. To identify patients who developed HAA from the full TRIUMPH cohort (nϭ4340), we excluded patients who underwent coronary artery bypass surgery (CABG) during the index admission (nϭ405) because anemia is exceedingly common after CABG and is a result of the CABG surgery itself and because the post-CABG outcomes (including health status recovery) are different from patients treated with percutaneous coronary intervention or medications alone. Thus, we were concerned about introducing substantial confounding in our analyses by retaining CABG patients. In addition, we excluded patients who did not survive to hospital discharge (nϭ17) and those with chronic anemia at admission (nϭ950) because our principal focus was development of HAA and its association with postdischarge outcomes. Additionally, there were missing admission and/or discharge hemoglobin levels for 59 patients, resulting in a final population of 2909 patients. To contrast the outcomes of HAA with chronic anemia, we included the 950 patients with baseline chronic anemia in our outcomes analyses. Vital status data at 12 months was available for the vast majority of patients (3837 of 3859, 99.4%); SF-12 PCS scores were available for 1880 patients at 1 month, 1714 at 6 months, and 1664 at 12 months.
Definitions
Hemoglobin values were abstracted by trained data collectors at each center. Admission hemoglobin was defined as the first in-hospital hemoglobin (g/dL) value available for each patient. If a patient was transferred to a TRIUMPH center from another hospital, the initial hemoglobin at the transferring facility was obtained and used as the admission value. Discharge hemoglobin was defined as the last hemoglobin value obtained within 48 hours of discharge from the hospital. HAA was defined as absence of anemia on admission but development of anemia at discharge. For our primary analyses, anemia was defined using age-, sex-, and race-specific criteria was described by Beutler and Waalen as a hemoglobin value Ͻ13.7 g/dL for white men ages 20 to 59 years, 13.2 g/dL for white men Ն60 years, 12.9 g/dL for black men ages 20 to 59, 12.7 g/dL for black men Ն60 years, 12.2 g/dL for white women, and 11.5 g/dL for black women. This classification has been previously shown to be more accurate than the World Health Organization definition (WHO). 9 In light of its common use in prior cardiovascular literature, we also conducted sensitivity analyses using WHO diagnostic criteria for anemia (Hgb Ͻ13.0 g/dL in men, Hgb Ͻ12.0 g/dL in women). 10 HAA was defined as absence of anemia on admission but development of anemia at discharge using these criteria. Anemia was further categorized as severe (Hgb Յ9.0 g/dL), moderate (Hgb 9.1 to 11.0 g/dL), or mild (Hgb Ͼ11.0 g/dL). 6 Data regarding in-hospital blood transfusions were systematically collected by the data abstracters. Because using discharge hemoglobin to define anemia severity could result in misclassification of a patients' anemia severity among those who received a blood transfusion during hospitalization, we subtracted the number of units transfused (1 g/dL Hgb per unit transfused) from the discharge hemoglobin and used this derived value to assign patients to the appropriate anemia severity category. All transfused patients were categorized as having HAA.
Bleeding episodes were also systematically recorded by data abstracters using the Thrombolysis In Myocardial Infarction (TIMI) classification. 11 TIMI major bleeding was defined as intracranial hemorrhage, retroperitoneal hemorrhage, or a Hgb decline Ն5 g/dL. TIMI minor bleeding was assigned if the drop in Hgb was 3 to 5 g/dL in the setting of observed bleeding. Any bleeding episode with a decline in Hgb Ͻ3 g/dL was classified as TIMI minimal bleeding. All TIMI categories accounted for blood transfusion, with adjustment of Hgb values by 1 g/dL per unit transfused. Bleeding site was recorded as cardiac catheterization site, gastrointestinal, retroperitoneal, or other.
Health status was assessed using the Short Form-12 Physical Component Summary score (SF-12 PCS). The SF-12 is a valid and reliable instrument with scores ranging from 0 to 100, with higher scores representing better health status. 12 A score of 50 is normalized to the mean health status of the US population, and each 10 points represents 1 standard deviation from that mean.
Statistical Analyses
Baseline characteristics, in-hospital treatments, in-hospital complications, and laboratory values of patients who developed HAA were compared with those who did not have anemia at either admission or discharge. We also compared the frequency of in-hospital bleeding among those with and without HAA, as well as within categories of HAA severity. For the 12-month outcome analyses, we divided HAA into mild and moderate-severe anemia, comparing each HAA cate- Values are expressed as meanϮSD or n (%).
In-hospital medication variables include the following individual medications: GP IIb/IIIa inhibitor (abciximab, eptifibatide, tirofiban); thienopyridine (clopidogrel, ticlopidine); anticoagulant (intravenous heparin, low-molecularweight heparin such as enoxaparin or dalteparin, or other heparinoid); and antithrombin (bivalirudin, lepirudin).
LVEF indicates left ventricular ejection fraction; PCI, percutaneous coronary intervention; ACE, angiotensinconverting enzyme; ARB, angiotensin receptor blocker; STEMI, ST-segment elevation myocardial infarction; and IQR, interquartile range. gory to a reference category of no anemia. We also included patients with chronic anemia at admission in outcome analyses, comparing them with those without anemia. For descriptive purposes, we present categorical data as frequencies and differences between groups were compared using 2 or Fisher exact tests, as appropriate. Continuous variables were reported as meanϮstandard deviation, and differences were compared using independent t tests. The Wilcoxon rank-sum test was used to compare patients' length of stay due to its skewed distribution, and results are reported as the median and interquartile range.
We used hierarchical modified Poisson regression within hospital site to identify patient characteristics independently associated with HAA. Typical analyses use logistic regression to estimate adjusted odds ratios, which are then generally interpreted as relative risks. However, in this study the event being modeled (HAA) was not rare, in which case odds ratios are poor estimates of relative risk. To address this issue, we estimated adjusted relative risks directly using a modified Poisson regression model with a robust error variance. 13 Variables included in the model were either identified a priori as clinically important or differed between the groups in bivariate comparisons (PϽ0.05). These included enrolling hospital, age, sex, race (white versus other), diabetes, hypertension, chronic kidney disease, history of chronic heart failure, left ventricular ejection fraction Ͻ40%, prior CABG, prehospital use of aspirin or clopidogrel, acute noncardiac condition on arrival, in-hospital acute renal failure, MI type (ST-segment elevation versus non-ST-segment elevation), in-hospital percutaneous coronary intervention, inhospital treatment with GP IIb/IIIa inhibitor, antiplatelet agents or anticoagulants, cardiogenic shock, in-hospital bleeding in each TIMI category, and length of stay. Missing covariate data in the predictors of HAA model were minimal and included 1 missing value for race, 1 missing value for length of stay, and 1 missing value for left ventricular ejection fraction. Additionally, these models were repeated after including baseline Hgb as a continuous variable to understand the influence of initial Hgb on identification of independent correlates of anemia.
We calculated the proportion of patients with HAA at each hospital using shrinkage estimation from a hierarchical model including site as a random effect (with no additional covariates), which accounts for sites with small enrollments by pulling their rates toward the overall mean. To further describe variation in HAA, rates across hospitals were quantified by the median rate ratio. This is the median value of the relative risk for HAA development for 2 patients with identical characteristics admitted to 2 randomly selected hospitals. 14 To evaluate the association between HAA and long-term outcomes, we used log-rank tests and generated Kaplan-Meier curves for crude morality analyses and compared crude SF-12 PCS scores using 1-way ANOVA. Mortality was defined as time to event and was censored at 12-months after hospital discharge among patients surviving at 12-months. To better understand the contribution of in-hospital bleeding on HAA-associated mortality risk, Kaplan-Meier curves were also generated for the subgroups of patients with HAA who did and did not have documented bleeding, and their 12-month mortality was compared using log-rank test. We then used multivariable proportional hazards regression models for 12-month mortality and tested the proportional hazards assumption in the fully adjusted model using Schoenfeld residuals. To assess changes in health status, we used a multivariable repeated measures linear regression model with a random effect for patient and an autoregressive within-patient covariance structure for Short Form-12 physical component scores (SF-12 PCS) that incorporated 1-, 6-, and 12month health status assessments. 15 The use of full-data maximum likelihood methods, accounting for within-patient correlation, cor- rects for missing-data biases that are attributable to other observed patient characteristics. These models were adjusted for hospital site and the GRACE discharge to 6-month mortality risk score, 16 which is strongly predictive of long-term mortality and incorporates important potential confounders. Variables included in GRACE score are age, heart rate, systolic blood pressure, creatinine, history of congestive heart failure, prior MI, in-hospital PCI or CABG, ST-segment depression on the initial ECG, and elevated cardiac biomarkers. Presence and severity of bleeding were also included in the models, using dummy variables for TIMI major, minor and minimal bleeding to understand whether the prognostic impact of HAA is independent of bleeding presence and severity. The models evaluating the relationship between SF-12 PCS scores and HAA also adjusted for baseline SF-12 PCS.
Finally, several sensitivity analyses were conducted. First, models were repeated using the WHO definition of anemia. Second, analyses were repeated after excluding patients who received blood transfusion. Finally, we examined the association between HAA and 12-month mortality after adjusting for baseline Hgb. All analyses were conducted with SAS version 9.1.3 (SAS Institute, Cary, NC) and R version 2.7.2 (R Development Core Team (2006)-R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3 to 900051-07 to 0, http://www.R-project.org).
Results
HAA Incidence, Severity, and Baseline Patient Characteristics
Among 2909 AMI patients without anemia at admission, 1321 (45.4%) developed HAA. Baseline demographics, comorbidities, in-hospital characteristics, and treatments of patients with and without HAA are compared in Table 1 . Hemoglobin at admission, discharge, and change during hospitalization are presented in Table 2 . Hgb declined by a mean of 2.6Ϯ1.4 g/dL during hospitalization among patients with HAA but also declined modestly (by 1.0Ϯ1.3 g/dL) in those who did not develop HAA (PϽ0.001). The majority of cases of HAA were mild (973, 73.7%), whereas 292 (22.1%) had moderate anemia and 56 (4.24%) had severe anemia. There were important clinical differences between patients with and without HAA, as detailed in Table 1 .
Bleeding and HAA
Although documented in-hospital bleeding was more common in patients with HAA as compared with those without HAA, the majority (1143 of 1321 patients, 86.5%) of patients with HAA did not have any documented in-hospital bleeding ( Table 3 ). The mean hemoglobin decline in patients with recorded bleeding was 3.1Ϯ1.9 g/dL, as compared with 1.6Ϯ1.4 in those who did not have a bleeding episode. As the severity of HAA increased among patients with documented bleeding, a greater proportion of bleeding events were classified as TIMI major and TIMI minor bleeds. Although in-hospital bleeding was significantly more common in patients with severe HAA than those with less severe or no HAA, nearly half of patients with severe HAA still had no significant bleeding episode.
Independent Correlates of HAA
Independent correlates of HAA are presented in Figure 1 . In-hospital bleeding was associated with a greater likelihood of developing HAA (TIMI minimal bleeding: relative risk [RR] of 1.36; 95% confidence interval [CI], 1.25 to 1.48; TIMI minor: RR of 1.72; 95% CI, 1.39 to 2.13; TIMI major bleeding RR of 1.72; 95% CI, 1.46 to 2.02). Additional patient characteristics associated with developing HAA included age, female sex, white race, and chronic kidney disease as well as development of cardiogenic shock, acute renal failure, presentation with ST-segment elevated myocardial infarction, and treatment with glycoprotein IIb/IIIa inhibitors. Longer length of stay was also associated with HAA.
We also repeated this model with the addition of baseline Hgb, which was strongly associated with HAA (RR, 0.70; 95% CI, 0.66 to 0.75) per 1 g/dL increase in baseline Hgb. Because we used diagnostic thresholds for anemia that were age-, sex-, and race-specific and thus accounted for the lower normal Hgb values in African Americans, older patients, and women, the inclusion of baseline Hgb in the models artificially altered the point estimates for these demographic variables as predictors of HAA (eg, female sex was associated with less risk of HAA whereas white race was more strongly associated with HAA after inclusion of baseline Hgb; data not presented). The addition of baseline Hgb to the model did not substantially alter point estimates for any other HAA correlates.
Variability in HAA Across Hospitals
The unadjusted incidence of HAA across all TRIUMPH hospitals varied between 33% and 69%. After generating shrinkage estimates, the incidence ranged from 35% to 66% (Figure 2) . The median rate ratio for site was 1.13 (95% CI, 1.07 to 1.23), indicating that 2 patients with identical demographic and clinical characteristics presenting to 2 randomly selected hospitals can be 13% more or less likely to develop HAA.
Outcomes Associated With HAA
To assess the prognostic significance of HAA, we compared outcomes across HAA severity categories to patients with no anemia and chronic anemia at the time of admission. Impor- tant differences in 12-month survival were associated with the development and severity of HAA. Mortality was lowest in those without HAA (40 of 1581, 2.6%), rising progressively in those with mild HAA (34 of 966, 3.6%), moderatesevere HAA (29 of 345, 8.4%), and chronic anemia (117 of 945, 12.6%) (PϽ0.001; Figure 3A ). Among patients who developed HAA, survival did not differ on the basis of presence or absence of documented bleeding ( Figure 3B ).
Using no anemia as the reference group, there was no unadjusted or multivariable-adjusted association between mild HAA and mortality (Figure 4) . In contrast, moderatesevere HAA and chronic anemia were strongly associated with mortality. Even after adjusting for GRACE 6-month mortality score and the presence and severity of bleeding, patients with moderate-severe HAA had an increased risk of death as compared with those without anemia (HR, 1.82; 95% CI, 1.11 to 2.98). Similarly, chronic anemia was strongly and independently associated with 12-month mortality (HR, 2.31; 95% CI, 1.57 to 3.40). The proportional hazards assumption was met for the fully adjusted mortality model (Pϭ0.233).
At baseline, the SF-12 PCS scores were higher in those without anemia and in patients with mild HAA and lower in those with moderate-severe HAA and chronic anemia (no anemia: 44.9Ϯ11.6; mild HAA: 44.2Ϯ11.6; moderate-severe HAA: 40.1Ϯ12.6; chronic anemia: 37.3Ϯ12.8; PϽ0.001). Adjusting for baseline health status and incorporating 1-, 6-, and 12-month SF-12 scores, mean follow-up SF-12 PCS scores were lower in those with chronic anemia with a trend toward lower scores in those with moderate-severe HAA in comparison to those without anemia ( Figure 5 ). Patients with mild HAA and no anemia had similar SF-12 PCS scores.
We conducted a series of sensitivity analyses to assess the robustness of our primary analysis. Using the WHO definition of anemia, excluding those who received blood transfusion, and adjusting the outcomes models for baseline Hgb all resulted in similar findings (data not shown).
Discussion
We found that almost half of patients who had normal hemoglobin at admission developed anemia by hospital discharge in this large, prospective, multicenter AMI cohort. Although inpatient bleeding was a strong independent predictor of HAA, most patients with HAA did not have a documented bleeding event during hospitalization, suggesting that HAA is not simply a surrogate for in-hospital bleeding events. Importantly, moderate-severe HAA was associated with increased long-term mortality, independent of AMI severity and regardless of the presence and extent of bleeding, suggesting that HAA is prognostically important in its own right and may represent a target for prevention efforts. Supporting that there is opportunity to minimize the risk of developing HAA, we observed significant variability in incidence of HAA across hospital sites.
Prior studies have established the short-and long-term prognostic significance of chronic anemia, [2] [3] [4] [5] and more recent reports have examined the association between changes in Hgb during hospitalization and outcomes. 7 Aronson et al 7 found that declines in Hgb during AMI hospitalization were independently associated with mortality; however, their anal- yses included both patients with baseline anemia and newonset anemia during hospitalization. Because patients with chronic anemia presumably have poorer hematopoetic reserve or greater baseline comorbidity, potentially predisposing them to large Hgb declines. It is unclear from these data whether the relationship between inpatient Hgb decline and survival is present among those with normal baseline Hgb. Our work extends these insights by defining a population with acute anemia, a potentially preventable condition, and observing that moderate-severe HAA is associated with an increased risk of mortality of similar magnitude to those with chronic anemia, even after adjustment for the presence and severity of bleeding. Our findings also extend prior observations by Sattur et al, 17 who reported, in a single-center study, that incident anemia in PCI patients was independently associated with long-term mortality. The anemia threshold used in that study (Hgb Ͻ10 g/dL) was relatively low, potentially leading to overestimation of the association between anemia and outcomes. Our study provides new insights by examining a large, contemporary, multicenter cohort, focusing on patients with AMI and using standard definitions of anemia. Moreover, our analyses include a broad range of outcomes (including health status), and provide important new data about the variability of HAA across hospitals.
Our findings have important clinical implications. Several of the correlates of HAA are also associated with chronic anemia and bleeding in AMI patients (such as age, female sex, acute heart failure, and chronic kidney disease) 2, 7, 18, 19 and probably identify a high-risk population with poor hematopoetic reserve. On the other hand, some independent correlates are hospital-based processes and complications (use of glycoprotein IIb/IIIa inhibitors and bleeding) and could be targets for prevention efforts. Several of these variables are associated with bleeding, 18 -20 and the use of bleeding avoidance measures, such as radial artery access for percutaneous coronary intervention, closure devices, smaller sheaths, or alternative antithrombotic agents such as bivalirudin in place of heparin and a glycoprotein IIb/IIIa inhibitor, present potential opportunities for improvement. [21] [22] [23] [24] Additionally, the strong association between moderate-severe HAA and 12-month mortality, even after adjusting for the presence and severity of bleeding, indicates that HAA is distinct from bleeding and is clinically important in its own right. Although the major causes of HAA among those without documented bleeding remain unclear, it is possible that it is related to subclinical blood loss (such as frequent phlebotomy), undetected minor periprocedural bleeding ("nuisance bleeding"), inadequate hematopoietic response, or a combination of processes. Our findings indicate that additional emphasis on prevention of HAA, a process distinct from overt bleeding in many cases, could be just as important as prevention of major bleeding. Further studies are needed to better define specific causes of HAA, to develop the tools that can prospectively identify patients at high risk for HAA at the time of admission, and to study the feasibility, comparative clinical effectiveness and cost effectiveness of various HAA Figure 5 . Association of mild HAA, moderate-severe HAA, and chronic anemia with physical functioning over 12 months of follow-up. Repeated-measures health status scores, comparing mean difference in SF-12 PCS scores in each anemia category over 12 months of follow-up controlling for baseline SF-12 PCS score. Results are presented as mean points difference in SF-12 PCS score comparing each anemia category to the reference group without anemia (95% CI).
prevention strategies (such as reducing phlebotomy and the use of bleeding avoidance strategies), so that the most effective and least costly measures can be adopted. The first step in this process, however, is to raise awareness about the incidence and prognostic importance of HAA, which is the main objective of our study.
Our findings should be interpreted in the context of several potential limitations. We used discharge hemoglobin values to define HAA since nadir hemoglobin values were not available. This approach may underestimate the prevalence of HAA; however, given the relatively short duration of hospitalization (median, 3.0 days; interquartile range, 2.0 to 4.0) it is unlikely that a substantial proportion of HAA cases were missed. More importantly, our goal was to examine prognosis after discharge, and discharge Hgb is the most accurate assessment of patients' anemia status at that time. It is also possible that unrecognized, minor bleeding episodes (ie, "nuisance bleeding") were not detected despite careful prospective collection of bleeding data. Even if this were the case, however, the association between bleeding and adverse outcomes has only been demonstrated for more severe categories of bleeding, and not for mild bleeding. These "nuisance" bleeding events are currently considered by many to be unimportant and are not systematically tracked either clinically or as end points in clinical trials. 25 Our data highlight the need to better understand if HAA may in part be caused by "nuisance" bleeding and whether minor bleeding events have a greater impact on patient outcomes than previously thought. Another possible limitation is that some misclassification of anemia severity occurred in patients with in HAA who received blood transfusions before discharge hemoglobin assessment. However, we adjusted the discharge hemoglobin values for in-hospital blood transfusion to minimize this issue and performed sensitivity analyses excluding patients who received a blood transfusion. It is also possible that frequent scheduled phlebotomy was associated with HAA; however, data on blood draws were not collected in this registry. Our definition of chronic anemia was any anemia present at admission, which could have captured subacute cases in addition to those with long term anemia. Finally, these observational data do not allow us to draw conclusions about causal relationships between HAA and mortality, and it remains unclear whether HAA is a marker for, or a mediator of, poor outcomes.
In conclusion, we found that HAA is common in AMI patients who are treated medically or with percutaneous coronary intervention and varies significantly across hospitals. Development of moderate-severe HAA is associated with higher mortality and worse health status in the first year after AMI, independent of documented in-hospital bleeding. Better understanding of whether prevention of HAA is feasible and can improve patient outcomes is needed.
Sources of Funding
Drs Salisbury and Spertus are funded in part by the American Heart Association-PRT Outcomes Research Fellowship Program and Center Grant, respectively. Dr Kosiborod is funded in part by the American Heart Association-PRT Career Development Award in Implementation Research. The TRIUMPH study was funded by a grant from the NHLBI (P50 HL 077113).
Disclosures
Dr Masoudi served on an advisory board for Amgen and provided blinded end-point adjudication for Axio Research. S. Rathore has received an AHRQ dissertation grant. Dr Wang has received research grants from Bristol-Myers Squibb, Daichi, Heartscape, Johnson & Johnson, Eli Lilly, Sanofi-Aventus, Schering Plough, and The Medicines Company. Dr Bach has received research grants from AstraZeneca, Schering-Plough, Merck, Bristol-Myers Squibb, The Medicines Company, and Eli Lilly; has served on a speakers' bureau for Bristol-Myers Squibb, Sanofi-Aventis; and has served as a consultant (clinical events committee) for Roche, Eli Lilly, Forest, and Wyeth/Pfizer. Dr Marso has received research grants Boston Scientific, The Medicines Company, Volcano Corporation, Amylin, and Terumo, and has served as a consultant to or on an advisory board for Novo Nordisk, The Medicines Company, and Abbott Vascular. Dr Spertus has received research grants from NHLBI, AHA-PRT Outcomes Centers, ACCF, Johnson & Johnson, Amgen, Lilly, Evaheart, and Sanofi-Aventis; has received other research support from Roche and Atherotech; has ownership interest in Health Outcomes Sciences, copyright to SAQ, KCCQ, PAQ; and has served as a consultant to or on an advisory board for St Jude Medical, United Healthcare, and Novartis. Dr Kosiborod has received an AHA-PRT Career Development Award.
